Rebecca Miksad MD, MPH, MMS
Associate Professor, Hematology & Medical Oncology
820 Harrison Ave | (617) 638-7011ramiksad@bu.edu
Sections
Hematology & Medical Oncology
Biography
Rebecca Miksad is a medical oncologist and health outcomes researcher who is Associate Professor at Boston Medical Center and serves as Chief Medical Officer at Color Health.
Dr. Rebecca Miksad is a mission-driven Physician-Scientist with extensive expertise in cancer and patient-centric health technology, clinical trials and real world evidence research. As Chief Medical Officer at Color Health, she oversees Color’s medical and clinical functions, driving the expansion of cancer screening, diagnostics, care navigation, and survivorship tools for program participants. At Boston Medical Center, Rebecca established the first High Risk Cancer Genetics clinic at Boston Medical Center, Dr. Miksad is an internationally recognized leader in oncology, clinical trials and data science, with over 100 scientific publications.
Dr. Miksad previously founded and led the Strategic Affairs team and Research Unit at Flatiron Health, developing pioneering healthtech products and establishing industry standards for real-world data. Her work has influenced FDA guidances and advanced Health Equity initiatives. She previously directed the Gastrointestinal Cancer program at Beth Israel Deaconess Medical Center and conducted NIH-funded research. Clinically trained as a medical oncologist, Dr. Miksad holds an MD with Honors from Cornell University and an MPH in Clinical Effectiveness from Harvard University. She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).
Rebecca maintains a clinical practice at Boston Medical Center. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally.
Education
Medicine, MD, Cornell University
MMS/MMSc, Harvard University
MPH, Harvard School of Public Health
Economics, BA, Harvard University
Publications
Schneeweiss S, Miksad R. Bench to Budget: Integrated Evidence Generation for Medications. Clin Pharmacol Ther. 2025 Apr; 117(4):869-871. PMID: 40110751.
Published on 1/10/2025Miksad RA, Sarkar S. Evaluating Cancer Screening in the Era of Advanced Causal Inference Methods: Innovation, Adherence, and Health Equity Considerations. JCO Clin Cancer Inform. 2025 Jan; 9:e2400214. PMID: 39792989.
Published on 11/1/2024Miksad RA. Real-World Evidence in Regulatory Decision Making: Time for Evidence Integration. Clin Pharmacol Ther. 2024 Nov; 116(5):1153-1155. PMID: 39404680.
Published on 7/1/2024Canavan ME, Wang X, Ascha MS, Miksad RA, Showalter TN, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncol. 2024 Jul 01; 10(7):887-895. PMID: 38753341.
Published on 6/1/2024Miksad RA, Calip GS. Future of Cancer Treatment Guidelines: Integrating Real-World Insights for Equitable Cancer Care. JCO Clin Cancer Inform. 2024 Jun; 8:e2400081. PMID: 38959447.
Published on 5/1/2024Miksad RA, Ryals CA. The US Food and Drug Administration Dual Mandate for Rapid Drug Review and Equity. JAMA Netw Open. 2024 May 01; 7(5):e2411447. PMID: 38691364.
Published on 1/9/2024Vidal GA, Jain N, Fisher A, Sheinson D, Lofgren KT, Ma E, Yu E, Comment L, Miksad R, Sincan M, Martin RL, Zuniga R, Daniel D. Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncol Pract. 2024 Mar; 20(3):370-377. PMID: 38194619.
Published on 8/31/2023Guadamuz JS, Wang X, Ryals CA, Miksad RA, Snider J, Walters J, Calip GS. Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011-2022. JNCI Cancer Spectr. 2023 Aug 31; 7(5). PMID: 37707536.
Published on 6/20/2023Canavan M, Wang X, Ascha M, Miksad R, Showalter TN, Calip G, Gross CP, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. J Clin Oncol. 2023 Oct 20; 41(30):4729-4738. PMID: 37339389.
Published on 6/1/2023Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open. 2023 Jun 01; 6(6):e2316642. PMID: 37273206.